How to Help Your Patients Find Voydeya in Stock: A Provider's Guide

For PNH patients with ongoing extravascular hemolysis, timely access to Voydeya (danicopan) can be the difference between continuing to require transfusions or achieving hemoglobin normalization. As the managing provider, your proactive workflow choices have an outsized impact on how quickly your patients can start therapy. This guide is designed to give you an actionable, step-by-step approach to minimizing Voydeya access delays.

Step 1: Get REMS-Certified Before Your First Voydeya Patient

If you are not yet enrolled in the VOYDEYA REMS program, do it now — not when you write your first prescription. REMS certification takes time, and an uncertified prescriber cannot issue a valid Voydeya prescription. Enroll at voydeyarems.com or by calling 1-888-765-4747. Your office staff should also be familiar with the enrollment form requirements so they can process new patients efficiently.

Step 2: Identify Voydeya Candidates Early and Start Vaccination Immediately

The ideal Voydeya candidate is a PNH patient who has been on eculizumab or ravulizumab for at least 6 months and continues to experience EVH (Hgb ≤9.5 g/dL, elevated reticulocytes, and/or ongoing transfusion dependence). Once you identify this pattern, do the following at that same visit — before even deciding on Voydeya:

Check vaccination status for meningococcal and pneumococcal vaccines per current ACIP recommendations for complement inhibitor recipients

Order or administer needed vaccines immediately — the 2-week post-vaccination requirement is a hard prerequisite, and getting vaccines on that visit removes weeks of future delay

Order baseline labs: LFTs, lipid panel, CBC with reticulocyte count, LDH — needed for PA and for establishing pre-treatment baselines

Step 3: Submit a Complete Prior Authorization on Day One

Incomplete PA submissions are the leading cause of preventable access delays. Train your PA coordinator to gather all required elements before submitting. A complete PA submission for Voydeya includes:

PNH diagnosis: ICD-10 D59.5, confirmed by flow cytometry showing >10% PNH clone size in granulocytes

Documentation of ≥6 months on stable eculizumab or ravulizumab with specific drug name, dose, and administration frequency

Recent lab values (within 4–8 weeks) demonstrating EVH: Hgb, ARC, LDH, total bilirubin

Transfusion documentation if patient has required pRBC transfusions in the prior 4–12 weeks

Vaccination records (meningococcal and pneumococcal vaccines, dates administered)

Letter of medical necessity (use Alexion's template from alexionaccessnavigator.com as a starting point; customize to match payer-specific criteria)

Step 4: Enroll Patients in Alexion OneSource Simultaneously

Submit the Prescriber and Patient Enrollment Form to OneSource at the same time you submit the PA — not after. OneSource case managers proactively follow up on PA status, can advocate for expedited review, coordinate with Onco360, and help patients navigate financial assistance programs. Contact OneSource by fax or call 1-888-765-4747. Visit alexiononesource.com.

Step 5: Have a Bridging Plan Ready for the PA Wait Period

PA processing typically takes 5–14 business days for complete submissions. For patients with active, symptomatic EVH during this period:

Optimize C5 inhibitor dosing to ensure maximal IVH suppression during the wait

Consider transfusion support if hemoglobin levels require it

Request expedited PA review if the patient's clinical status is urgent — most plans offer 24–72 hour expedited timelines with appropriate clinical documentation

Step 6: If Denied, Appeal With Peer-to-Peer Immediately

PA denials for Voydeya are common on first submission and frequently overturned on appeal. When denied, request a peer-to-peer review with the payer's medical director as soon as possible. Come prepared with: the specific denial rationale, serial lab trends showing EVH progression, peer-reviewed publications including the ALPHA trial (Lancet Haematol, 2023), and the FDA-approved prescribing information. External appeal success rates for rare disease specialty drugs can exceed 50%.

Step 7: Use medfinder as a Patient Resource for Specialty Access

For providers who want additional support navigating specialty drug access for patients, medfinder for providers offers pharmacy-reaching services to determine where specialty medications can be dispensed. For more on the current access situation, see our patient-facing Voydeya shortage update for 2026.